Article Information
History
- July 2, 2021.
Article Versions
- You are currently viewing Version 1 of this article (July 2, 2021 - 13:54).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ricardo Ariel Zimerman, MD1,
- Daniel do Nascimento Fonseca, MD2,
- Michael do Nascimento Correia, MD3,
- Renan Nascimento Barros, MD4,
- Dirce Costa Onety, MD5,
- Karla Cristina Petruccelli Israel, MD5,6,
- Emilyn Oliveira Guerreiro2,
- José Erique Miranda Medeiros2,
- Raquel Neves Nicolau2,
- Luiza Fernanda Mendonça Nicolau2,
- Rafael Xavier Cunha2,
- Maria Fernanda Rodrigues Barroco2,
- Patrícia Souza da Silva2,
- Raysa Wanzeller de Souza Paulain, MD4,
- Claudia Elizabeth Thompson, PhD7,
- Andy Goren, MD8 and
- Flávio Adsuara Cadegiani, MD, PhD8,9,*
- 1Hospital da Brigada Militar, Porto Alegre, Brazil
- 2Samel & Oscar Nicolau Hospitals, Manaus, Brazil
- 3Hospital Regional José Mendes, Itacoatiara, Amazonas, Brazil
- 4Hospital Municipal Jofre Cohen, Parintins, Amazonas, Brazil
- 5Centro de Doenças Renais do Amazonas, Manaus, Brazil
- 6Programa de Pós-Graduação em Medicina Tropical – FMT/UEA, Manaus, Brazil
- 7Department of Pharmacosciences, Universidade Federal de Ciências da Saúde de Porto Alegre
- 8Applied Biology, Inc. Irvine, CA, USA
- 9Corpometria Institute, Brasilia, Brazil
- ↵*Corresponding author
: Flavio Adsuara Cadegiani, MD, PhD, Applied Biology, Inc., 17780 Fitch, Irvine, CA 92614, f.cadegiani{at}gmail.com
Posted July 02, 2021.
Proxalutamide (GT0918) Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
